{"entity":{"id":"nct07297212","kind":"trial","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","aka":[],"tldr":"A phase 2 trial of PM8002, Bevacizumab and Temozolomide in glioma & glioblastoma, run by BioNTech SE, now recruiting.","summary":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma is a phase 2 interventional study registered as NCT07297212 by BioNTech SE, with 75 participants planned, started 2026-01-15 and due to reach its primary completion in 2028-01. Interventions recorded: Pumitamig, Bevacizumab and Temozolomide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07297212","url":"https://clinicaltrials.gov/study/NCT07297212"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","monoclonal-antibody"],"targets":[],"drugs":["pm8002","bevacizumab","temozolomide"],"companies":["biontech","bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07297212","phase":"2","setting":"A Phase II, Multi-site, Open-label Trial Evaluating the Safety and Efficacy of Pumitamig and Bevacizumab as Monotherapy and Pumitamig in Combination With Temozolomide in Patients With Recurrent Glioblastoma","sponsor":"BioNTech SE","participation":[{"nct":"NCT07297212","source":"https://clinicaltrials.gov/study/NCT07297212","fetchedAt":"2026-10-07T16:55:39.854Z","studySha256":"716ff97a7e666898654390f4e480a8ae86976b85213a9c7cf8b5362e83fe3df0","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-29","leadSponsor":"BioNTech SE","collaboratorCount":2,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":75,"enrolmentType":"ESTIMATED","siteCount":6,"recruitingSiteCount":6,"countries":["China"]}],"started":"2026-01-15","startedType":"actual","enrolled":75,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07297212/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}